Stacie Hudgens, CEO of Clinical Outcomes Solutions, on the Effects of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir Regimen on Health‐related Quality of Life for Patients with Hepatitis C

Linda Howard Stacie Hudgens

Stacie Hudgens, Chief Executive Officer, Strategic Lead Regulatory and Access, at COS, has an article published in Liver International: ‘Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C’ To view this article, please click here. To find out more about Stacie Hudgens, please click here.

Clinical Outcomes Solutions CEO Publishes Article on Understanding Health-related Quality of Life in an Ovarian Maintenance Clinical Trial

Linda Howard Stacie Hudgens

Stacie Hudgens MSc, Chief Executive Officer, Strategic Lead Regulatory and Access, has a manuscript published in The Lancet this month, entitled ‘Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial’. This is a paper focused on understanding health-related quality of life in an ovarian maintenance …